Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: The role of IL-6 signaling and Nrf2/AKR1C axis identification

Biochemical Pharmacology

Volumn 86, Issue 7, 2013, Pages 872-887

  Chen, Chih Cheng ^a,b,c   Chu, Chia Bao ^d   Liu, Ko Jiunn ^d   Huang, Chi Ying F ^e   Chang, Jang Yang ^d,f   Pan, Wen Yu ^d   Chen, Huang Hui ^d   Cheng, Yun Hsia ^a   Lee, Kuan Der ^a,b   Chen, Miao Fen ^a,b   Kuo, Ching Chuan ^d,g   Chen, Li Tzong ^d,f,g,h  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^h KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Acquired resistance; IL 6 signaling; Nrf2 AKR1C axis; Oxaliplatin

Indexed keywords

ALDO KETO REDUCTASE 1C1; ALDO KETO REDUCTASE 1C2; ALDO KETO REDUCTASE 1C3; GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 80; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; NEUTRALIZING ANTIBODY; OXALIPLATIN; OXIDOREDUCTASE; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION PROFILING; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; UPREGULATION;

Α-METHYLCINNAMIC ACID; Γ-GLUTAMYL CYSTEINE SYNTHETASE CATALYTIC SUBUNIT; Γ-GLUTAMYL CYSTEINE SYNTHETASE MODIFIER SUBUNIT; ACQUIRED RESISTANCE; AKR1CS; ALDO-KETO REDUCTASE FAMILY MEMBERS (E.G. AKR1C1, AKR1C2, OR AKR1C3); AN OXALIPLATIN-RESISTANT HUMAN GASTRIC CARCINOMA CELL LINE (TSGH-S3); ANTIOXIDANT RESPONSE ELEMENT; ARE; CIS-DIAMMINEDICHLOROPLATINUM(II) (CDDP); CISPLATIN; ERCC-1; ERK; EXCISION REPAIR CROSS-COMPLEMENTING-1; EXTRACELLULAR SIGNAL-RELATED KINASE; FFA; FLUFENAMIC ACID; GASTROINTESTINAL TRACT; GCLC; GCLM; GI; GLUTATHIONE REDUCTASE; GLUTATHIONE S-TRANSFERASE; GR; GST; HEME OXYGENASE-1; HIF-1Α; HO-1; HYPOXIA-INDUCIBLE FACTOR-1Α; IL -6R/GP130; IL -6R/GP80; IL-6; IL-6 RECEPTOR Α SUBUNIT; IL-6 RECEPTOR Β SUBUNIT; IL-6 SIGNALING; INTERLEUKIN-6; JAK1; JAK2; JANUS KINASE 1; JANUS KINASE 2; MAPK; MCA; MITOGEN-ACTIVATED PROTEIN KINASE; NAD(P)H:QUINONE OXIDOREDUCTASE; NQO-1; NRF2; NRF2/AKR1C AXIS; NUCLEAR FACTOR ERYTHROID 2-RELATED FACTOR 2; OXALIPLATIN; PHENOLPHTHALEIN; PHOSPHATIDYLINOSITOL 3-KINASE; PI3K; PPTH; S3; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3; STAT3; THIOREDOXIN REDUCTASE; TR; TYK2; TYROSINE KINASE 2;

20-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; ANTIOXIDANT RESPONSE ELEMENTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTERLEUKIN-6; NF-E2-RELATED FACTOR 2; ORGANOPLATINUM COMPOUNDS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84884702038     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.07.025     Document Type: Article

References (54)

1. Y. Becouarn, C. Agostini, N. Trufflandier, and V. Boulanger Oxaliplatin: available data in non-colorectal gastrointestinal malignancies Critical Reviews in Oncology/Hematology 40 2001 265 272 (Pubitemid 33111071)
2. B. Gruenberger, J. Schueller, U. Heubrandtner, F. Wrba, D. Tamandl, and K. Kaczirek Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study Lancet Oncology 11 2010 1142 1148
3. W. Sun, D. Sohal, D.G. Haller, K. Mykulowycz, M. Rosen, and M.C. Soulen Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma Cancer 117 2011 3187 3192
4. D. Cunningham, N. Starling, S. Rao, T. Iveson, M. Nicolson, and F. Coxon Capecitabine and oxaliplatin for advanced esophagogastric cancer New England Journal of Medicine 358 2008 36 46
5. L. Kelland The resurgence of platinum-based cancer chemotherapy Nature Reviews Cancer 7 2007 573 584 (Pubitemid 47106628)
6. M. Mishima, G. Samimi, A. Kondo, X. Lin, and S.B. Howell The cellular pharmacology of oxaliplatin resistance European Journal of Cancer 38 2002 1405 1412 (Pubitemid 34686853)
7. I. Gourdier, M. Del Rio, L. Crabbe, L. Candeil, V. Copois, and M. Ychou Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma FEBS Letters 529 2002 232 236
8. Z.B. Ding, B. Hui, Y.H. Shi, J. Zhou, Y.F. Peng, and C.Y. Gu Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation Clinical Cancer Research 17 2011 6229 6238
9. D.L. Roberts, K.J. Williams, R.L. Cowen, M. Barathova, A.J. Eustace, and S. Brittain-Dissont Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells British Journal of Cancer 101 2009 1290 1297
10. B. Desoize, and C. Madoulet Particular aspects of platinum compounds used at present in cancer treatment Critical Reviews in Oncology/Hematology 42 2002 317 325 (Pubitemid 34615692)
11. S.B. Howell, R. Safaei, C.A. Larson, and M.J. Sailor Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs Molecular Pharmacology 77 2010 887 894
12. R. Metzger, C.G. Leichman, K.D. Danenberg, P.V. Danenberg, H.J. Lenz, and K. Hayashi ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy Journal of Clinical Oncology 16 1998 309 316 (Pubitemid 28041614)
13. H.J. Jun, M.J. Ahn, H.S. Kim, S.Y. Yi, J. Han, and S.K. Lee ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation British Journal of Cancer 99 2008 167 172 (Pubitemid 351920246)
14. C.C. Chen, L.T. Chen, T.C. Tsou, W.Y. Pan, C.C. Kuo, and J.F. Liu Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil British Journal of Cancer 97 2007 334 344
15. L.J. Su, C.W. Chang, Y.C. Wu, K.C. Chen, C.J. Lin, and S.C. Liang Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme BMC Genomics 8 2007 140
16. D. Kube, U. Holtick, M. Vockerodt, T. Ahmadi, B. Haier, and I. Behrmann STAT3 is constitutively activated in Hodgkin cell lines Blood 98 2001 762 770
17. H.H. Chen, Y.T. Chen, Y.W. Huang, H.J. Tsai, and C.C. Kuo 4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling Free Radical Biology and Medicine 52 2012 1054 1066
18. V. Sriuranpong, J.I. Park, P. Amornphimoltham, V. Patel, B.D. Nelkin, and J.S. Gutkind Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system Cancer Research 63 2003 2948 2956 (Pubitemid 36667168)
19. P.C. Heinrich, I. Behrmann, S. Haan, H.M. Hermanns, G. Muller-Newen, and F. Schaper Principles of interleukin (IL)-6-type cytokine signalling and its regulation Biochemical Journal 374 2003 1 20 (Pubitemid 37046923)
20. P.C. Heinrich, I. Behrmann, G. Muller-Newen, F. Schaper, and L. Graeve Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway Biochemical Journal 334 Pt. 2 1998 297 314 (Pubitemid 28448572)
21. M. Mihara, M. Hashizume, H. Yoshida, M. Suzuki, and M. Shiina IL-6/IL-6 receptor system and its role in physiological and pathological conditions Clinical Science (London) 122 2012 143 159
22. T.M. Penning, Y. Jin, S. Steckelbroeck, T. Lanisnik Rizner, and M. Lewis Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins Molecular and Cellular Endocrinology 215 2004 63 72 (Pubitemid 38337424)
23. A. Ghosal, Y. Yuan, W. Tong, A.D. Su, C. Gu, and S.K. Chowdhury Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor Drug Metabolism and Disposition: The Biological Fate of Chemicals 39 2011 510 521
24. C. Li, B. Lu, R.M. Garbaccio, E.S. Tasber, M.E. Fraley, and G.D. Hartman Stereospecific reduction of a potent kinesin spindle protein (KSP) inhibitor in human tissues Biochemical Pharmacology 79 2010 1526 1533
25. Z. Tong, A. Chandrasekaran, H. Li, Y. Rotshteyn, J.C. Erve, and W. Demaio In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone Drug Metabolism and Disposition: The Biological Fate of Chemicals 38 2010 801 807
26. M. Chen, A.O. Adeniji, B.M. Twenter, J.D. Winkler, D.W. Christianson, and T.M. Penning Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer Bioorganic and Medicinal Chemistry Letters 22 2012 3492 3497
27. F.X. Ruiz, S. Porte, O. Gallego, A. Moro, A. Ardevol, and A. Del Rio-Espinola Retinaldehyde is a substrate for human aldo-keto reductases of the 1C subfamily Biochemical Journal 440 2011 335 344
28. S. Steckelbroeck, B. Oyesanmi, Y. Jin, S.H. Lee, H.J. Kloosterboer, and T.M. Penning Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily Journal of Pharmacology and Experimental Therapeutics 316 2006 1300 1309 (Pubitemid 43345306)
29. P. Brozic, B. Golob, N. Gomboc, T.L. Rizner, and S. Gobec Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3) Molecular and Cellular Endocrinology 248 2006 233 235
30. M. McMahon, K. Itoh, M. Yamamoto, S.A. Chanas, C.J. Henderson, and L.I. McLellan The Cap 'n' collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes Cancer Research 61 2001 3299 3307 (Pubitemid 32695017)
31. X.J. Wang, J.D. Hayes, and C.R. Wolf Generation of a stable antioxidant response element-driven reporter gene cell line and its use to show redox-dependent activation of nrf2 by cancer chemotherapeutic agents Cancer Research 66 2006 10983 10994 (Pubitemid 44876998)
32. M. Kobayashi, and M. Yamamoto Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation Antioxidants and Redox Signalling 7 2005 385 394 (Pubitemid 40279806)
33. J.W. Kaspar, S.K. Niture, and A.K. Jaiswal Nrf2:INrf2 (Keap1) signaling in oxidative stress Free Radical Biology and Medicine 47 2009 1304 1309
34. H. Motohashi, T. O'Connor, F. Katsuoka, J.D. Engel, and M. Yamamoto Integration and diversity of the regulatory network composed of Maf and CNC families of transcription factors Gene 294 2002 1 12 (Pubitemid 35291008)
35. K. Itoh, M. Mochizuki, Y. Ishii, T. Ishii, T. Shibata, and Y. Kawamoto Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2) Molecular and Cellular Biology 24 2004 36 45 (Pubitemid 38010033)
36. J. Scheller, and S. Rose-John Interleukin-6 and its receptor: from bench to bedside Medical Microbiology and Immunology 195 2006 173 183 (Pubitemid 44600378)
37. Z.T. Schafer, and J.S. Brugge IL-6 involvement in epithelial cancers Journal of Clinical Investigation 117 2007 3660 3663 (Pubitemid 350224077)
38. S.A. Duffy, J.M. Taylor, J.E. Terrell, M. Islam, Y. Li, and K.E. Fowler Interleukin-6 predicts recurrence and survival among head and neck cancer patients Cancer 113 2008 750 757
39. N.J. Sullivan, A.K. Sasser, A.E. Axel, F. Vesuna, V. Raman, and N. Ramirez Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells Oncogene 28 2009 2940 2947
40. C.C. Chen, W.C. Chen, C.H. Lu, W.H. Wang, P.Y. Lin, and K.D. Lee Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor International Journal of Radiation Oncology, Biology, Physics 76 2010 1214 1224
41. T. Ara, and Y.A. Declerck Interleukin-6 in bone metastasis and cancer progression European Journal of Cancer 46 2010 1223 1231
42. W.L. Huang, H.H. Yeh, C.C. Lin, W.W. Lai, J.Y. Chang, and W.T. Chang Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells Molecular Cancer 9 2010 309
43. N.Y. Hsu, H.C. Ho, K.C. Chow, T.Y. Lin, C.S. Shih, and L.S. Wang Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer Cancer Research 61 2001 2727 2731
44. L.S. Wang, K.C. Chow, Y.C. Wu, T.Y. Lin, and W.Y. Li Inverse expression of dihydrodiol dehydrogenase and glutathione-S-transferase in patients with esophageal squamous cell carcinoma International Journal of Cancer 111 2004 246 251
45. W. Ax, M. Soldan, L. Koch, and E. Maser Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction Biochemical Pharmacology 59 2000 293 300 (Pubitemid 30001756)
46. H.B. Deng, H.K. Parekh, K.C. Chow, and H. Simpkins Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells Journal of Biological Chemistry 277 2002 15035 15043 (Pubitemid 34952580)
47. E. Selga, V. Noe, and C.J. Ciudad Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis Biochemical Pharmacology 75 2008 414 426 (Pubitemid 350298467)
48. A. Kobayashi, M.I. Kang, H. Okawa, M. Ohtsuji, Y. Zenke, and T. Chiba Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2 Molecular and Cellular Biology 24 2004 7130 7139 (Pubitemid 39014439)
49. A.K. Jaiswal Nrf2 signaling in coordinated activation of antioxidant gene expression Free Radical Biology and Medicine 36 2004 1199 1207 (Pubitemid 38526313)
50. C.M. Mahaffey, H. Zhang, A. Rinna, W. Holland, P.C. Mack, and H.J. Forman Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma Free Radical Biology and Medicine 46 2009 1650 1657
51. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, and M. Ohtsuji Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Research 68 2008 1303 1309 (Pubitemid 351346836)
52. S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, and N. Haraguchi Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer Clinical Cancer Research 15 2009 3423 3432
53. D. Ren, N.F. Villeneuve, T. Jiang, T. Wu, A. Lau, and H.A. Toppin Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism Proceedings of the National Academy of Sciences of the United States of America 108 2011 1433 1438
54. J.M. Cho, S. Manandhar, H.R. Lee, H.M. Park, and M.K. Kwak Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance Cancer Letters 260 2008 96 108